Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | GPR6 | P46095 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.43 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 2/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5220987 | 0.81 | USP30 (0.57) | USP30MALT1HRH3CHRM4PANK3 | |
| SCHEMBL22686737 | 0.80 | USP30 (0.56) | USP30MALT1HRH3CHRM4PANK3 | |
| SCHEMBL21227887 | 0.75 | CKS1B (0.53) | USP30MALT1HRH3CHRM4PANK3 | |
| SCHEMBL3282462 | 0.75 | USP30 (0.47) | USP30MALT1HRH3CHRM4PANK3 | |
| SCHEMBL3064435 | 0.74 | MCHR1 (0.46) | USP30MCHR1UTS2RCCR2 | |
| SCHEMBL4970792 | 0.73 | MCHR1 (0.55) | MCHR1UTS2RGRM5 | |
| SCHEMBL1990732 | 0.73 | MALT1 (0.59) | USP30MALT1HRH3CHRM4PANK3 | |
| SCHEMBL22686015 | 0.72 | POLB (0.55) | USP30MALT1PANK3 | |
| SCHEMBL29655962 | 0.72 | POLB (0.55) | USP30MALT1PANK3 | |
| SCHEMBL25818614 | 0.71 | KDM4E (0.58) | USP30MALT1HRH3CHRM4PANK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267717-A1 | Novel Heterocyclic NF-kB Inhibitors | 4SC AG (DE) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267717-A1 | Novel Heterocyclic NF-kB Inhibitors | NFKB2, NFKBIA, NFRKB | USP30 2835/4885MCHR1 3580/4885MALT1 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.